SCHEMBL536590

SCHEMBL536590

COC(=O)c1cccc2nc[nH]c12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.46
LMNA P02545 2/20 0.46
ALDH1A1 P00352 2/20 0.46
HSD17B10 Q99714 2/20 0.46
MAPT P10636 1/20 0.46
HPGD P15428 1/20 0.46
HTT P42858 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
NR4A2 P43354 4/20 0.44
MAP2K1 Q02750 1/20 0.44
KMT2A Q03164 2/20 0.43
ATM Q13315 2/20 0.43
GAA P10253 1/20 0.43
TSHR P16473 1/20 0.43
MEN1 O00255 1/20 0.43
CREBBP Q92793 2/20 0.42
CFTR P13569 1/20 0.42
PIM1 P11309 1/20 0.42
PIM3 Q86V86 1/20 0.42
POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Potassium SCHEMBL29729324 0.98 KDM4E (0.45) KDM4ELMNAALDH1A1HSD17B10MAPT
SCHEMBL665999 0.83 KDM4E (0.49) KDM4ELMNAALDH1A1HSD17B10MAPT
SCHEMBL4081935 0.83 CLEC4M (0.57) KDM4ELMNAALDH1A1HSD17B10HPGD
SCHEMBL1382500 0.83 TSHR (0.56) KDM4ELMNAALDH1A1HSD17B10MAPT
SCHEMBL2646903 0.81 PARP1 (0.41) KDM4ELMNAALDH1A1MAPTHPGD
SCHEMBL52077 0.80 PARP1 (0.56) KDM4ELMNAALDH1A1HSD17B10HPGD
SCHEMBL453513 0.80 KEAP1 (0.49) KDM4ELMNAALDH1A1MAPTHTT
SCHEMBL6016867 0.79 CLEC4M (0.40) KDM4EALDH1A1HSD17B10HPGDHTT
SCHEMBL11789735 0.79 TSHR (0.57) KDM4ELMNAALDH1A1HSD17B10HPGD
SCHEMBL663849 0.78 PARP1 (0.56) KDM4EALDH1A1HSD17B10MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117106189-A Metal organic framework artificial hydrolase and preparation method and application thereof 华南理工大学 2023-11-24 CN claimed
CN-109415327-A Azilsartan intermediate, Azilsartan and their manufacturing method 株式会社德山 2019-03-01 CN claimed
JP-4658940-B2 2011-03-23 JP claimed
JP-2006528213-A 2006-12-14 JP claimed
EP-1636216-A1 BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS Sanofi-Aventis Deutschland GmbH (DE) 2006-03-22 EP claimed
WO-2004101553-A1 BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2004-11-25 WO claimed
US-12479842-B2 Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease UNIVERSITE DE MONTREAL (CA) 2025-11-25 US disclosed
US-20250270207-A1 PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE UNIVERSITE DE MONTREAL (CA) 2025-08-28 US disclosed
CN-119644685-A High-efficiency positive photoresist stripping solution and preparation method thereof 浙江尚能实业股份有限公司 2025-03-18 CN disclosed
US-12139488-B2 Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease Université de Montréal (CA) 2024-11-12 US disclosed
US-20240317747-A1 PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE Université de Montréal (CA) 2024-09-26 US disclosed
US-12060353-B2 Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease Université de Montréal (CA) 2024-08-13 US disclosed
US-20240217971-A1 PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE Université de Montréal (CA) 2024-07-04 US disclosed
WO-2003106430-A1 BENZIMIDAZOLE INHIBITORS OF POLY(ADP-RIBOSYL) POLYMERASE PFIZER INC. (US) 2003-12-24 WO disclosed
EP-1339402-A2 BENZOAZEPINE AND BENZODIAZEPINE DERIVATIVES AND THEIR USE AS PARP INHIBITORS GUILFORD PHARMACEUTICALS INC. (US) 2003-09-03 EP disclosed
US-20030022883-A1 Compounds and their use EISAI INC. 2003-01-30 US disclosed
WO-2002044183-A2 BENZOAZEPINE AND BENZODIAZEPINE DERIVATIVES AND THEIR USE AS PARP INHIBITORS GUILFORD PHARMACEUTICALS INC. (US) 2002-06-06 WO disclosed
WO-2001074786-A1 HETEROBIARYLSULPHONAMIDES AND THEIR USE AS PDE 7 INHIBITORS DARWIN DISCOVERY LIMITED (GB) 2001-10-11 WO disclosed
US-3988155-A CYANINE SENSITIZING DYES FUJI PHOTO FILM CO., LTD. (JA) 1976-10-26 US disclosed
US-3985563-A Silver halide photographic emulsion FUJI PHOTO FILM CO., LTD. (JA) 1976-10-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030022883-A1 Compounds and their use PARP1, PARP2, PARP3 KDM4E 1317/4885LMNA 187/4885ALDH1A1 1256/4885
US-20250270207-A1 PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE BRAF, NRAS, KRAS KDM4E 2883/4885LMNA 2658/4885ALDH1A1 1636/4885
US-20240317747-A1 PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE BRAF, NRAS, KRAS KDM4E 2883/4885LMNA 2658/4885ALDH1A1 1636/4885
US-12139488-B2 Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease BRAF, NRAS, KRAS KDM4E 2883/4885LMNA 2658/4885ALDH1A1 1636/4885
US-12060353-B2 Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease BRAF, NRAS, KRAS KDM4E 2883/4885LMNA 2658/4885ALDH1A1 1636/4885
US-12479842-B2 Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease BRAF, NRAS, DPYD KDM4E 2840/4885LMNA 2678/4885ALDH1A1 1619/4885
US-20240217971-A1 PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE BRAF, NRAS, DPYD KDM4E 2840/4885LMNA 2678/4885ALDH1A1 1619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.